|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
GONADOTROPHIN SECRETION WHICH IS STIMULATED BY THE GONADORELIN, IS INHIBITED BY THE DRUG
|
GONADOTROPHIN SECRETION WHICH IS STIMULATED BY THE GONADORELIN, IS INHIBITED BY THE DRUG
|
BARBITURATE EFFECT IS POTENTIATED SO DOSE SHOULD BE REDUCED
|
BARBITURATE EFFECT IS POTENTIATED SO DOSE SHOULD BE REDUCED
|
BARBITURATE EFFECT IS POTENTIATED SO DOSE SHOULD BE REDUCED
|
BARBITURATE EFFECT IS POTENTIATED SO DOSE SHOULD BE REDUCED
|
BARBITURATE EFFECT IS POTENTIATED SO DOSE SHOULD BE REDUCED
|
BARBITURATE EFFECT IS POTENTIATED SO DOSE SHOULD BE REDUCED
|